Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This piece evaluates performance in retirement for Sp 500 vs Multi Asset approaches, outlining where each may excel under different conditions.
26,383 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
The U.S. shipbuilding industry is looming a 250,000-worker gap over the next decade, even as the Trump administration...
MoxiWorks unveils AI upgrades to its RISE platform, integrating marketing outreach with transaction tasks. Early clie...
HF Foods (HFFG) faces a pivotal year as Q1 2026 results unfold. This guide breaks down what to watch, how to interpre...
Dynatrace stock plummeted today after earnings beat but soft guidance signaled a cautious path ahead. This article br...
The trillion-dollar club is expanding, and a few ahead-of-the-curve signals can help you spot the next member. This g...
Astera Labs’ stock jumped after management laid out a firm timetable for a new switch and signaled growing opportunit...
A Philadelphia primary delivers a surprise win for a self-described 'proud troublemaker' democratic socialist, beatin...
A top DeFi security veteran warns that AI-coded agents are speeding up vulnerability discovery, forcing a reckoning o...
Aave secures FCA registrations for its UK entities and a MiCAR CASP license in Ireland, creating a regulated path fro...
Jim Cramer reframes Nokia’s story from a smartphone casualty to an AI infrastructure play, highlighting the stock’s s...
A once-high-flying growth stock tumbled 84% from its peak. This guide explains how to separate a genuine opportunity ...